Hospitals, Healthcare Systems, and Labs
Delivering actionable strategic insights and deal support as our clients navigate the increasingly complex Precision Medicine ecosystem
A raft of innovative technologies such as liquid biopsy, multi-omic diagnostic tests, and cell and gene therapies are set to change treatment paradigms and drive better clinical outcomes for patients. This offers huge opportunities and challenges for diagnostic and life science tools companies, who must make important strategic choices in how they structure their businesses via divestiture, acquisition or partnership to ensure that they can meet the future needs of their markets. Whether it be strategic advice, or support across the deal lifecycle, KPMG is helping our diagnostics and life science tools clients position themselves for future leadership.
